Badania w cukrzycy typu 2 z sercowo-naczyniowymi punktami końcowymi – podsumowanie i perspektywy

William T. Cefalu i wsp. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2018 Jan; 41(1): 14-31 (dostępny pełen tekst)

In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of
antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-term
cardiovascular outcomes trials (CVOTs) for safety. Since 2008, 9 CVOTs have been reported, 13 are under way, and 4 have been terminated …
Diabetes Care, styczeń 2018